141
Participants
Start Date
July 16, 2019
Primary Completion Date
December 23, 2021
Study Completion Date
December 23, 2021
Palbociclib
Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
Endocrine therapy
Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
Monash Health, Clayton
Peter MacCallum Cancer Centre, Melbourne
UNIMED Medical Institute, Hong Kong
National Cancer Center, Korea, Gyeonggi-do
Seoul National University Bundang Hospital, Seongnam
Korea Cancer Center Hospital, Seoul
Seoul National University College of Medicine, Seoul
Changhua Christian Hospital, Changhua
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
National Taiwan University Hospital, Taipei
Sun Yat-Sen Cancer Center, Taipei
Amagasaki General Medical Center, Amagasaki
University of Tsukuba Hospital, Tsukuba
Kyushu Cancer Center, Fukuoka
Sagara Hospital, Kagoshima
Kobe City Medical Center General Hospital, Kobe
Kyoto University Hospital, Kyoto
Aichi Cancer Center, Nagoya
Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka
Saitama Cancer Center, Saitama
Toranomon Hospital, Tokyo
Tokyo Metropolitan Komagome Hospital, Tokyo
Cancer Institute Hospital Of JFCR, Tokyo
Kyorin University Hospital, Tokyo
Kanagawa Cancer Center, Yokohama
Collaborators (1)
Pfizer
INDUSTRY
Kyoto Breast Cancer Research Network
OTHER